Amisulpride for the treatment of alcohol dependence
DOI:
https://doi.org/10.20882/adicciones.158Keywords:
amisulpride, naltrexone, topiramate, alcohol dependence and treatmentAbstract
Background: 6-month naturalistic, open-label trial to compare amisulpride versus topiramate and naltrexone as a treatment for patients with alcohol dependence, with assessments at enrolment and after 3 and 6 months of treatment. Methods: 274 alcohol-dependent patients who had been drinking heavily during the past month were included. Once detoxified, patients were assigned to one of three treatment groups (naltrexone 50 mgr per day, topiramate 200 mgr per day or amisulpride 100 mgr per day). Patients were assessed at baseline and after 3 and 6 months of follow-up. Outcome was measured using tools that assessed alcohol intake (EuropASI and Alcohol Timeline Followback), craving (OCDS), disability (WHO/DAS), and quality of life (EQ-5D); changes in biomarkers of alcohol intake were also noted. Results: at the 6-month follow-up patients taking amisulpride had poorer results than those taking topiramate in direct measures of alcohol intake (OCDS, alcohol intake, number of drinks per day and heavy drinking days), but no significant differences were found in these measures on comparing the amisulpride patients with those taking naltrexone. Conclusions: in this study, amisulpride, at a dose of 100 mgr per day, was less effective than topiramate, at a dose of 200 mg per day, but as effective as naltrexone, at a dose of 50 mg per day, for reducing alcohol intake and craving over the period of the study.References
Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998; 22: 3-9.
Koob GF, Le Moal M. Neurobiological mechanisms for opponent motivational processes in addiction. Phil Trans Soc B 2008; 363: 3113-23.
Srisurapanot M, JarusuraisinN. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267-280.
Mason BJ, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double – blind, placebo – controlled trials. CNS 2000; 5: 58-69.
Hughes JL, Cook CCH. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92: 381-96.
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361:1677-85.
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-51.
Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 2007; 27: 344-51.
Marra D, Warot D, Berlin I, Hispard E, Noticies C, Tilikete S. et al.
Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol Clin Exp Res 2002; 26: 1545-52.
World Health Organization. ICD-10, 10th Revision of the International
Classification of Diseases. Madrid: World Health Organization; 1992.
Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn N et al. (2004) Alcohol use. En: Ezzati M, Lopez AD, Rodgers A, Murray CJL editores. Comparative quantification of health risks: Global and regional burden of disease attributable to selected major risk factors, Vol. 1. Ginebra: Organización Mundial de la Salud; 2004. p. 995-1108.
Kokkevi A, Hartgers C. European adaptation of a multidimensional
assessment instrument for drug and alcohol dependence. Eur Addict Res 1995;1: 208-10.
Sobell LC, Sobell MB. Alcohol timeline followback user’s manual.
Toronto: Addiction Research Foundation; 1995.
Flórez G. Genética y comportamiento: Respuesta al tratamiento de deshabituación alcohólica en función de variables genéticas. Comunicación presentada a las XXXVI Jornadas Nacionales de Socidrogalcohol. Salamanca, 26, 27 y 28 de marzo de 2009.
Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin North Am 2001; 85: 1191-12.
Volpicelli JR, Pettinati HM, McLellan AT, McLellan T, O’Brien CHP.
Enhanced medication and treatment adherence for addiction treatment: the BRENDA model. New York: The Guilford Press; 2001.
Anton RF, Moak DH, Latham P. The obsessive compulsive drinking
scale: A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcoholism Clin Exp Res 1995; 19: 92-9.
Fagerström KO. Measuring degrees of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235-41.
Loranger AW, Sartorius N, Andreoli P, Berger P, Buchheim P, Channabasavanna SM et al. The international personality disorder examination. Arch Gen Psychiatry 1994; 51: 215-24.
Rollnick S, Heather N, Gold R, Hall W. Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 1992; 87: 743-54.
Janca A, Kastrup M, Katschnig H, López-Ibor JJJr, Mezzich JE,
Sartorius N . The World Health Organization Short Disability Assessment Schedule (WHO DAS – S): a tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatr Psychiatr Epidemiol 1996; 31: 349-54.
EuroQoL Group. EuroQoL – a new facility for the measurement
of health-related quality of life. Health Policy 1990; 16: 199-208.
Allen JP, Litten RZ, Strid N, Sillanaukee P. The role of biomarkers
in alcoholism medication trials. Alcoholism Clin Exp Res 2001; 25: 1119-25.
Lingjaerd O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987; 76: 1-100.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
Babor TF, Longabaugh R, Zweben A, Fuller RK, Stout RL, Anton RF et al. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol 1994; 12: 101-111.
Cisler RA, Zweben A. Development of a composite measure for
assessing alcohol treatment outcome: operationalization and validation. Alcoholism Clin Exp Res 1999; 23: 263-271.
Stout RL. Methodological and statistical considerations in measuring
alcohol treatment effects. Alcoholism Clin Exl Res 2003; 27: 1686-1691.
Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan
DM et al. COMBINE Study Research Group. Combined pharmacotherapies
and behavioral interventions for alcohol dependence – the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003-2017.
Nutt D. Alcohol and the brain: pharmacological insights for psychiatrists. Br J Psychiatry 1999; 175: 114-19.
Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation.
Science 1997; 278: 52-8.
Noble EP. Alcoholism and the dopaminergic system. Addict Biol
; 1: 333-348.
Heinz A, Beck A, Grüsser SM, Grace AA, Wrase J. Identifying the
neural circuitry of alcohol craving and relapse vulnerability. Addict Biol 2008; 14: 108-18.
Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet
O et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97.
Hermann D, Smolka MN, Wrase J, Klein S, Nikitopoulos J, Georgi A et al. Blockade of cue-induced brain activation of abstinent alcoholics by a single administration of amisulpride as measured with fMRI. Alcohol Clin Exp Res 2006; 30: 1349-54.
